Providing market intelligence for more than 35 years

In The News

mHealth Still Missing the Comfort Zone for Chronic Care Patients

A report from digital health analyst Parks Associates indicates 27 percent of those surveyed with a chronic condition want a mobile health device that tracks their condition – yet significant numbers also report that the devices they now have are too complicated to use or don’t work properly.

"Nearly one-half of type I diabetics and one-third of type II diabetics are interested in health monitoring devices such as glucometers, but a steep learning curve and difficult or counterintuitive directions could inhibit their usage of these devices and also prevent them from buying other connected health devices," Harry Wang, the group’s senior director of research, said in a press release accompanying the report. "Device and application manufacturers would benefit from improving the ease-of-use of these devices."

The study points to a continuation of missed opportunities in mHealth for both patients and their caregivers. 

From the article "mHealth Still Missing the Comfort Zone for Chronic Care Patients" by Eric Wicklund.

Previously In The News

Google Home now has a screen — and, soon, Spotify

The small, candle-shaped speaker equipped with the artificial-intelligence personal helper Google Assistant, has sold about 300,000 units since hitting the market in October, according to research and...

Western European Smart Thermostat Sales To Hit 1 Mln By 2020

Sales of smart thermostats in Western Europe are set to rise from less than 700,000 units in 2016 to more than one million units by 2020, according to a report on smart energy and water products by Pa...

Roku Plunges: 3 Reasons to Buy, 4 Reasons to Sell

Last August, Parks Associates reported that Roku controlled 37% of the streaming device market in the U.S., while Amazon, Google, and Apple held shares of 24%, 18%, and 15%, respectively. All three of...

The Simple Reason Why I Won't Buy Roku Inc.

Roku (NASDAQ:ROKU) went public on Sep. 28, its stock surging nearly 70% from its IPO price of $14 per share. The stock hit almost $30 the following day, but subsequently pulled back to the low $20s....